Peter Miller, Optinose CEO
June 13, 2022 10:45 AM EDT
R&D

Look­ing to ex­pand nasal spray in­di­ca­tion, Opti­nose se­cures sec­ond PhI­II win

Lei Lei Wu

News Reporter

Hav­ing got­ten ap­proval for its nasal polyps treat­ment four and a half years ago, Opti­nose is look­ing to ex­pand in­to a pa­tient pop­u­la­tion that’s 10 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times